THALLION PHARMACEUTICALS INC. Inactive Instrument
Thallion Pharmaceuticals Inc. Share Price
Equities
TLN
CA88327P1053
Biotechnology & Medical Research
Thallion Pharmaceuticals Inc is a Canada-based biotechnology company. The Company develops pharmaceutical products in the areas of infectious disease and oncology. Thallion Pharmaceuticals Inc's lead clinical program, Shigamabs, is a dual antibody product for the treatment of Shiga toxin-producing E. coli bacterial infections and has completed a Phase II clinical trial. The Company is a subsidiary of BELLUS Health.
| 1st Jan change | Capi. | |
|---|---|---|
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
